327 related articles for article (PubMed ID: 22421165)
1. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B
Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction pathway activity compensates dopamine D₂/D₃ receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [³H]raclopride and [³⁵S]GTPγS.
Farkas S; Nagy K; Jia Z; Hortobágyi T; Varrone A; Halldin C; Csiba L; Gulyás B
Brain Res; 2012 May; 1453():56-63. PubMed ID: 22480734
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
[TBL] [Abstract][Full Text] [Related]
4. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
5. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
6. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
8. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
9. A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.
Rebelo D; Oliveira F; Abrunhosa A; Januário C; Lemos J; Castelo-Branco M
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431672
[TBL] [Abstract][Full Text] [Related]
10. D2 receptor binding in dopa-responsive dystonia.
Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
[TBL] [Abstract][Full Text] [Related]
11. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.
Xu J; Hassanzadeh B; Chu W; Tu Z; Jones LA; Luedtke RR; Perlmutter JS; Mintun MA; Mach RH
Synapse; 2010 Jun; 64(6):449-59. PubMed ID: 20175227
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen.
Hillefors M; von Euler G
Neurochem Int; 2001 Jan; 38(1):31-42. PubMed ID: 10913686
[TBL] [Abstract][Full Text] [Related]
13. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
14. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
15. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
16. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.
Volkow ND; Wang GJ; Logan J; Alexoff D; Fowler JS; Thanos PK; Wong C; Casado V; Ferre S; Tomasi D
Transl Psychiatry; 2015 Apr; 5(4):e549. PubMed ID: 25871974
[TBL] [Abstract][Full Text] [Related]
17. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.
Politis M; Piccini P; Pavese N; Koh SB; Brooks DJ
Exp Neurol; 2008 Nov; 214(1):112-6. PubMed ID: 18723016
[TBL] [Abstract][Full Text] [Related]
18. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
19. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
20. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
